Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): an overview.

IF 3 4区 医学 Q1 Medicine Translational gastroenterology and hepatology Pub Date : 2021-07-25 eCollection Date: 2021-01-01 DOI:10.21037/tgh-20-149
Rolf Teschke, Axel Eickhoff, Johannes Schulze, Gaby Danan
{"title":"Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): an overview.","authors":"Rolf Teschke, Axel Eickhoff, Johannes Schulze, Gaby Danan","doi":"10.21037/tgh-20-149","DOIUrl":null,"url":null,"abstract":"<p><p>Herbal products including herbal medicines are worldwide used in large amounts for treating minor ailments and for disease prevention. However, efficacy of most herbal products has rarely been well documented through randomized controlled trials in line with evidence-based medicine concepts, which could be used to estimate the benefit/risk ratio. Instead, much better documented are adverse reactions such as liver injury associated with the consumption of some herbal products, so called herb-induced liver injury (HILI), which represents a clinical challenge. In order to establish HILI as valid diagnosis, the use of a diagnostic algorithms such as Roussel Uclaf Causality Assessment Method (RUCAM) is widely recommended, although physicians in some countries are reluctant to use RUCAM for their HILI cases. This review on worldwide HILI and RUCAM, developed as part of the artificial intelligence ideas, reveals that China is the leading country with 24 publications on HILI cases that were all assessed for causality using RUCAM, followed by Korea with 15 reports, Germany with 9 reports, the US with 7 reports, and Spain with 6 reports, whereas the remaining countries provided less than 4 reports. The total number of assessed HILI cases is 12,068 worldwide derived from 80 publications but in each report HILI case numbers were variable in a range from 1 up to 6,971. This figure compares with 46,266 cases of drug-induced liver injury (DILI) published worldwide from 2014 to early 2019 also assessed for causality by RUCAM. The original version of RUCAM was validated and established in 1993 and updated in 2016 that should be used in future HILI cases. RUCAM is an objective, structured, and validated method, specifically designed for liver injury. It is a scoring system including case data elements to be assessed and scored individually to provide a final score in five causality gradings. Among the 11,404/12,068 HILI (94.5%) cases assessable for evaluation, causality gradings were highly probable in 4.2%, probable in 15.5%, possible in 70.3%, and unlikely or excluded in 10.0%. To improve the future reporting of RUCAM based HILI cases, recommendations include the strict adherence to instructions outlined in the updated RUCAM and, in particular, to follow prospective data collection on the cases to ensure completeness of case data. In conclusion, RUCAM can well be used to assess causality in suspected HILI cases, and additional efforts are now required to increase the quality of the reported cases.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343418/pdf/tgh-06-20-149.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational gastroenterology and hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tgh-20-149","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Herbal products including herbal medicines are worldwide used in large amounts for treating minor ailments and for disease prevention. However, efficacy of most herbal products has rarely been well documented through randomized controlled trials in line with evidence-based medicine concepts, which could be used to estimate the benefit/risk ratio. Instead, much better documented are adverse reactions such as liver injury associated with the consumption of some herbal products, so called herb-induced liver injury (HILI), which represents a clinical challenge. In order to establish HILI as valid diagnosis, the use of a diagnostic algorithms such as Roussel Uclaf Causality Assessment Method (RUCAM) is widely recommended, although physicians in some countries are reluctant to use RUCAM for their HILI cases. This review on worldwide HILI and RUCAM, developed as part of the artificial intelligence ideas, reveals that China is the leading country with 24 publications on HILI cases that were all assessed for causality using RUCAM, followed by Korea with 15 reports, Germany with 9 reports, the US with 7 reports, and Spain with 6 reports, whereas the remaining countries provided less than 4 reports. The total number of assessed HILI cases is 12,068 worldwide derived from 80 publications but in each report HILI case numbers were variable in a range from 1 up to 6,971. This figure compares with 46,266 cases of drug-induced liver injury (DILI) published worldwide from 2014 to early 2019 also assessed for causality by RUCAM. The original version of RUCAM was validated and established in 1993 and updated in 2016 that should be used in future HILI cases. RUCAM is an objective, structured, and validated method, specifically designed for liver injury. It is a scoring system including case data elements to be assessed and scored individually to provide a final score in five causality gradings. Among the 11,404/12,068 HILI (94.5%) cases assessable for evaluation, causality gradings were highly probable in 4.2%, probable in 15.5%, possible in 70.3%, and unlikely or excluded in 10.0%. To improve the future reporting of RUCAM based HILI cases, recommendations include the strict adherence to instructions outlined in the updated RUCAM and, in particular, to follow prospective data collection on the cases to ensure completeness of case data. In conclusion, RUCAM can well be used to assess causality in suspected HILI cases, and additional efforts are now required to increase the quality of the reported cases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
根据鲁塞尔-乌克拉夫因果关系评估法(RUCAM)进行因果关系评估的全球 12,068 例草药诱发肝损伤(HILI)病例发表:综述。
包括草药在内的草药产品在世界各地被大量用于治疗小病和预防疾病。然而,大多数草药产品的疗效很少通过符合循证医学概念的随机对照试验得到充分证明,而这些试验可用于估算效益/风险比。反倒是一些草药产品的不良反应,如肝脏损伤,即所谓的草药诱发肝损伤(HILI),得到了较好的记录,这对临床是一个挑战。为了将 HILI 确立为有效的诊断,人们普遍推荐使用 Roussel Uclaf 因果关系评估法(RUCAM)等诊断算法,但一些国家的医生不愿意在 HILI 病例中使用 RUCAM。作为人工智能思想的一部分,本研究对全球 HILI 和 RUCAM 进行了回顾,结果显示,中国是使用 RUCAM 评估 HILI 因果关系的最主要国家,共发表了 24 篇 HILI 病例,其次是韩国,有 15 篇报告,德国有 9 篇报告,美国有 7 篇报告,西班牙有 6 篇报告,而其余国家提供的报告均少于 4 篇。从 80 份出版物中得出的全球经评估的 HILI 病例总数为 12,068 例,但每份报告中的 HILI 病例数都不尽相同,从 1 例到 6,971 例不等。这一数字与2014年至2019年初全球发表的46,266例药物性肝损伤(DILI)病例相比,RUCAM也对其进行了因果关系评估。RUCAM 的原始版本于 1993 年得到验证和确立,并于 2016 年进行了更新,应在未来的肝损伤病例中使用。RUCAM 是一种客观、结构化且经过验证的方法,专门针对肝损伤而设计。它是一个评分系统,包括对病例数据元素进行评估和单独评分,以提供五个因果关系分级的最终得分。在可评估的 11,404/12,068 例 HILI(94.5%)病例中,4.2% 的病例极有可能、15.5% 的病例可能、70.3% 的病例可能、10.0% 的病例不太可能或排除因果关系。为改进今后基于 RUCAM 的 HILI 病例报告,建议包括严格遵守更新版 RUCAM 中的说明,特别是对病例进行前瞻性数据收集,以确保病例数据的完整性。总之,RUCAM 可以很好地用于评估疑似 HILI 病例的因果关系,现在需要进一步努力提高报告病例的质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.20
自引率
0.00%
发文量
1
期刊介绍: Translational Gastroenterology and Hepatology (Transl Gastroenterol Hepatol; TGH; Online ISSN 2415-1289) is an open-access, peer-reviewed online journal that focuses on cutting-edge findings in the field of translational research in gastroenterology and hepatology and provides current and practical information on diagnosis, prevention and clinical investigations of gastrointestinal, pancreas, gallbladder and hepatic diseases. Specific areas of interest include, but not limited to, multimodality therapy, biomarkers, imaging, biology, pathology, and technical advances related to gastrointestinal and hepatic diseases. Contributions pertinent to gastroenterology and hepatology are also included from related fields such as nutrition, surgery, public health, human genetics, basic sciences, education, sociology, and nursing.
期刊最新文献
A fucoidan plant drink reduces Helicobacter pylori load in the stomach: a real-world study Risk of second cancer in esophageal squamous cell carcinoma and adenocarcinoma survivors: a population-based analysis in SEER dataset Application and effectiveness of an improved endoscopically guided nasojejunal tube placement technique in critically ill patients: a retrospective cohort study The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent Clostridiodes difficile Therapeutic advancement in inflammatory bowel disease by incorporating plant-based diet
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1